Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 453-458 , May 2006

Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination

  • Peter Laverman

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 24 3615054; fax: +31 24 3618942.
    • ,
  • I. Jolanda M. de Vries

      Affiliations

    • Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Nicole M. Scharenborg

      Affiliations

    • Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Annemiek de Boer

      Affiliations

    • Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Matthias Broekema

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Wim J.G. Oyen

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Carl G. Figdor

      Affiliations

    • Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Gosse J. Adema

      Affiliations

    • Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    • ,
  • Otto C. Boerman

      Affiliations

    • Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands

Received 22 December 2005 ,Revised 18 January 2006 ,Accepted 26 February 2006.

References 

  1. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296–306
  2. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091–5100
  3. de Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen G, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63:12–17
  4. van der Burg SH, Ras E, Drijfhout JW, Benckhuijsen WE, Bremers AJ, Melief CJ, et al. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol. 1995;44:189–198
  5. Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 2002;62:3184–3194
  6. Denkberg G, Cohen CJ, Lev A, Chames P, Hoogenboom HR, Reiter Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A. 2002;99:9421–9426
  7. Sette A, Sidney J, Del Guercio MF, Southwood S, Ruppert J, Dahlberg C, et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol. 1994;31:813–822
  8. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179:1005–1009
  9. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996;157:2539–2548
  10. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005;23:5779–5787
  11. Latron F, Pazmany L, Morrison J, Moots R, Saper MA, McMichael A, et al. A critical role for conserved residues in the cleft of HLA-A2 in presentation of a nonapeptide to T cells. Science. 1992;257:964–967
  12. Ljunggren HG, Stam NJ, Ohlen C, Neefjes JJ, Hoglund P, Heemels MT, et al. Empty MHC class I molecules come out in the cold. Nature. 1990;346:476–480

PII: S0969-8051(06)00035-7

doi: 10.1016/j.nucmedbio.2006.02.005

Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 453-458 , May 2006

Article Tools

* Image Usage & Resolution